Vardagsnefrologi-primärvård181030

Gunnar Johansson nefrologErland Olauson nefrolog

Risken för kardiovaskulär sjukdomökar med sjunkande GFR

*MDRD formelnGo A et al. N Engl J Med 2004;351:1296–1305

CVD40

35

30

25

20

15

10

5

0≥60 45–59 30–44 15–29 <15Å

lder

s st

anda

rdis

erad

inci

dens

av

ka

rdio

vask

ulär

a hä

ndel

ser

(per

100

per

son-

år)

eGFR (ml/min/1.73 m2)*

2.11 3.65

11.29

21.80

36.60

73,108 34,690 18,580 8809 3824Antal händelser

Cardiorenalt syndrom I-V

Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.

Ronco, C. et al. J Am Coll Cardiol 2008;52:1527-1539

CRS Type 1

Cardiorenalt syndrom I-V

Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.

Ronco, C. et al. J Am Coll Cardiol 2008;52:1527-1539

CRS Type 2

Cardiorenalt syndrom I-V

Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.

Ronco, C. et al. J Am Coll Cardiol 2008;52:1527-1539

CRS Type 3

Cardiorenalt syndrom I-V

Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.

Ronco, C. et al. J Am Coll Cardiol 2008;52:1527-1539

CRS Type 4

Cardiorenalt syndrom I-V

Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.

Ronco, C. et al. J Am Coll Cardiol 2008;52:1527-1539

CRS Type 5

”Nya” diabetes II läkemedel

• DDP-4 GFR < 30

• GLP-1Njurprotektiva

• SGLT2

Gunnar Erland

FOSFAT